Cholesteryl esters and ACAT

European Journal of Lipid Science and Technology

Volumn 114, Issue 6, 2012, Pages 624-633

  Pramfalk, Camilla ^a   Eriksson, Mats ^a   Parini, Paolo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesterol; Human; Lipoprotein

Indexed keywords

MUS;

EID: 84862206541     PISSN: 14387697     EISSN: 14389312     Source Type: Journal    
DOI: 10.1002/ejlt.201100294     Document Type: Review

References (86)

1. Chang, T. Y., Chang, C. C., Cheng, D., Acyl-coenzyme A:cholesterol acyltransferase. Annu. Rev. Biochem. 1997, 66, 613- 638.
2. Buhman, K. K., Accad, M., Novak, S., Choi, R. S. et al., Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat. Med. 2000, 6, 1341- 1347.
3. Anderson, R. A., Joyce, C., Davis, M., Reagan, J. W. et al., Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J. Biol. Chem. 1998, 273, 26747- 26754.
4. Lee, R. G., Willingham, M. C., Davis, M. A., Skinner, K. A., Rudel, L. L., Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates. J. Lipid Res. 2000, 41, 1991- 2001.
5. Meiner, V., Tam, C., Gunn, M. D., Dong, L. M. et al., Tissue expression studies on the mouse acyl-CoA:cholesterol acyltransferase gene (Acact): Findings supporting the existence of multiple cholesterol esterification enzymes in mice. J. Lipid Res. 1997, 38, 1928- 1933.
6. Lee, J. Y., Carr, T. P., Dietary fatty acids regulate acyl-CoA:cholesterol acyltransferase and cytosolic cholesteryl ester hydrolase in hamsters. J. Nutr. 2004, 134, 3239- 3244.
7. Lee, O., Chang, C. C., Lee, W., Chang, T. Y., Immunodepletion experiments suggest that acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. J. Lipid Res. 1998, 39, 1722- 1727.
8. Chang, C. C., Sakashita, N., Ornvold, K., Lee, O. et al., Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J. Biol. Chem. 2000, 275, 28083- 28092.
9. Smith, J. L., Rangaraj, K., Simpson, R., Maclean, D. J. et al., Quantitative analysis of the expression of ACAT genes in human tissues by real-time PCR. J. Lipid Res. 2004, 45, 686- 696.
10. Sakashita, N., Miyazaki, A., Takeya, M., Horiuchi, S. et al., Localization of human acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) in macrophages and in various tissues. Am. J. Pathol. 2000, 156, 227- 236.
11. Sakashita, N., Miyazaki, A., Chang, C. C., Chang, T. Y. et al., Acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) is induced in monocyte-derived macrophages: In vivo and in vitro studies. Lab. Invest. 2003, 83, 1569- 1581.
12. Parini, P., Davis, M., Lada, A. T., Erickson, S. K. et al., ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation 2004, 110, 2017- 2023.
13. Jiang, Z. Y., Jiang, C. Y., Wang, L., Wang, J. C. et al., Increased NPC1L1 and ACAT2 expression in the jejunal mucosa from Chinese gallstone patients. Biochem. Biophys. Res. Commun. 2009, 379, 49- 54.
14. Cases, S., Novak, S., Zheng, Y. W., Myers, H. M. et al., ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J. Biol. Chem. 1998, 273, 26755- 26764.
15. Joyce, C., Skinner, K., Anderson, R. A., Rudel, L. L., Acyl-coenzyme A:cholesteryl acyltransferase 2. Curr. Opin. Lipidol. 1999, 10, 89- 95.
16. Joyce, C. W., Shelness, G. S., Davis, M. A., Lee, R. G. et al., ACAT1 and ACAT2 membrane topology segregates a serine residue essential for activity to opposite sides of the endoplasmic reticulum membrane. Mol. Biol. Cell. 2000, 11, 3675- 3687.
17. Lin, S., Cheng, D., Liu, M. S., Chen, J., Chang, T. Y., Human acyl-CoA:cholesterol acyltransferase-1 in the endoplasmic reticulum contains seven transmembrane domains. J. Biol. Chem. 1999, 274, 23276- 23285.
18. Lin, S., Lu, X., Chang, C. C., Chang, T. Y., Human acyl-coenzyme A:cholesterol acyltransferase expressed in chinese hamster ovary cells: Membrane topology and active site location. Mol. Biol. Cell 2003, 14, 2447- 2460.
19. Song, B. L., Qi, W., Yang, X. Y., Chang, C. C. et al., Organization of human ACAT-2 gene and its cell-type-specific promoter activity. Biochem. Biophys. Res. Commun. 2001, 282, 580- 588.
20. Yang, L., Lee, O., Chen, J., Chen, J. et al., Human acyl-coenzyme A:cholesterol acyltransferase 1 (acat1) sequences located in two different chromosomes (7 and 1) are required to produce a novel ACAT1 isoenzyme with additional sequence at the N terminus. J. Biol. Chem. 2004, 279, 46253- 46262.
21. Li, B. L., Li, X. L., Duan, Z. J., Lee, O. et al., Human acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) gene organization and evidence that the 4.3-kilobase ACAT-1 mRNA is produced from two different chromosomes. J. Biol. Chem. 1999, 274, 11060- 11071.
22. Chen, J., Zhao, X. N., Yang, L., Hu, G. J. et al., RNA secondary structures located in the interchromosomal region of human ACAT1 chimeric mRNA are required to produce the 56-kDa isoform. Cell Res. 2008, 18, 921- 936.
23. Yang, L., Chen, J., Chang, C. C., Yang, X. Y. et al., A stable upstream stem-loop structure enhances selection of the first 5'-ORF-AUG as a main start codon for translation initiation of human ACAT1 mRNA. Acta Biochim. Biophys. Sin. (Shanghai) 2004, 36, 259- 268.
24. Chang, T. Y., Li, B. L., Chang, C. C., Urano, Y., Acyl-Coenzyme a:Cholesterol Acyltransferases. Am J. Physiol. Endocrinol. Metab. 2009, 297, E1- 9.
25. Uelmen, P. J., Oka, K., Sullivan, M., Chang, C. C. et al., Tissue-specific expression and cholesterol regulation of acylcoenzyme A:cholesterol acyltransferase (ACAT) in mice. Molecular cloning of mouse ACAT cDNA, chromosomal localization, and regulation of ACAT in vivo and in vitro. J. Biol. Chem. 1995, 270, 26192- 26201.
26. Katsuren, K., Tamura, T., Arashiro, R., Takata, K. et al., Structure of the human acyl-CoA:cholesterol acyltransferase-2 (ACAT-2) gene and its relation to dyslipidemia. Biochim. Biophys. Acta 2001, 1531, 230- 240.
27. Accad, M., Smith, S. J., Newland, D. L., Sanan, D. A. et al., Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J. Clin. Invest. 2000, 105, 711- 719.
28. Yagyu, H., Kitamine, T., Osuga, J., Tozawa, R. et al., Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J. Biol. Chem. 2000, 275, 21324- 21330.
29. Fazio, S., Major, A. S., Swift, L. L., Gleaves, L. A. et al., Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J. Clin. Invest. 2001, 107, 163- 171.
30. Su, Y. R., Dove, D. E., Major, A. S., Hasty, A. H. et al., Reduced ABCA1-mediated cholesterol efflux and accelerated atherosclerosis in apolipoprotein E-deficient mice lacking macrophage-derived ACAT1. Circulation 2005, 111, 2373- 2381.
31. Bryleva, E. Y., Rogers, M. A., Chang, C. C., Buen, F. et al., ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. USA 2010, 107, 3081- 3086.
32. Willner, E. L., Tow, B., Buhman, K. K., Wilson, M. et al., Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA 2003, 100, 1262- 1267.
33. Bell, T. A. III, Kelley, K., Wilson, M. D., Sawyer, J. K., Rudel, L. L., Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1396- 1402.
34. Brown, J. M., Bell, T. A. III, Alger, H. M., Sawyer, J. K. et al., Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J. Biol. Chem. 2008, 283, 10522- 10534.
35. Alger, H. M., Brown, J. M., Sawyer, J. K., Kelley, K. L. et al., Inhibtion of acyl-coenzyme a:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol associated steatosis by enhancing hepatic triglyceride mobilization. J. Biol. Chem. 2010, 285, 14267- 14274.
36. Lee, R. G., Kelley, K. L., Sawyer, J. K., Farese, R. V. Jr. et al., Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ. Res. 2004, 95, 998- 1004.
37. Lee, R. G., Shah, R., Sawyer, J. K., Hamilton, R. L. et al., ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. J. Lipid Res. 2005, 46, 1205- 1212.
38. Repa, J. J., Buhman, K. K., Farese, R. V. Jr., Dietschy, J. M., Turley, S. D., ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: Impact on hepatic cholesterol homeostasis. Hepatology 2004, 40, 1088- 1097.
39. Turley, S. D., Valasek, M. A., Repa, J. J., Dietschy, J. M., Multiple mechanisms limit the accumulation of unesterified cholesterol in the small intestine of mice deficient in both ACAT2 and ABCA1. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299, G1012- G1022.
40. Temel, R. E., Lee, R. G., Kelley, K. L., Davis, M. A. et al., Intestinal cholesterol absorption is substantially reduced in mice deficient in both ABCA1 and ACAT2. J. Lipid Res. 2005, 46, 2423- 2431.
41. Brown, M. S., Goldstein, J. L., The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89, 331- 340.
42. Kim, J. B., Spotts, G. D., Halvorsen, Y. D., Shih, H. M. et al., Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain. Mol. Cell Biol. 1995, 15, 2582- 2588.
43. Skoog, T., Dichtl, W., Boquist, S., Skoglund-Andersson, C. et al., Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur. Heart J. 2002, 23, 376- 383.
44. Chang, T. Y., Chang, C. C., Lu, X., Lin, S., Catalysis of ACAT may be completed within the plane of the membrane: A working hypothesis. J. Lipid Res. 2001, 42, 1933- 1938.
45. Chang, C. C., Lee, C. Y., Chang, E. T., Cruz, J. C. et al., Recombinant acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) purified to essential homogeneity utilizes cholesterol in mixed micelles or in vesicles in a highly cooperative manner. J. Biol Chem. 1998, 273, 35132- 35141.
46. Matsuda, H., Hakamata, H., Miyazaki, A., Sakai, M. et al., Activation of acyl-coenzyme A:cholesterol acyltransferase activity by cholesterol is not due to altered mRNA levels in HepG2 cells. Biochim. Biophys. Acta 1996, 1301, 76- 84.
47. Seo, T., Oelkers, P. M., Giattina, M. R., Worgall, T. S. et al., Differential modulation of ACAT1 and ACAT2 transcription and activity by long chain free fatty acids in cultured cells. Biochemistry 2001, 40, 4756- 4762.
48. Liang, J. J., Oelkers, P., Guo, C., Chu, P. C. et al., Overexpression of human diacylglycerol acyltransferase 1, acyl-coa:cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells. J. Biol. Chem. 2004, 279, 44938- 44944.
49. Temel, R. E., Hou, L., Rudel, L. L., Shelness, G. S., ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins. J. Lipid Res. 2007, 48, 1618- 1627.
50. Rudel, L. L., Davis, M., Sawyer, J., Shah, R., Wallace, J., Primates highly responsive to dietary cholesterol up-regulate hepatic ACAT2, and less responsive primates do not. J. Biol. Chem. 2002, 277, 31401- 31406.
51. Roberts, C. K., Liang, K., Barnard, R. J., Kim, C. H., Vaziri, N. D., HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X. Kidney Int. 2004, 66, 1503- 1511.
52. Jiao, R., Guan, L., Yang, N., Peng, C. et al., Frequent cholesterol intake up-regulates intestinal NPC1L1, ACAT2, and MTP. J. Agric. Food Chem. 2010, 58, 5851- 5857.
53. Pramfalk, C., Angelin, B., Eriksson, M., Parini, P., Cholesterol regulates ACAT2 gene expression and enzyme activity in human hepatoma cells. Biochem. Biophys. Res. Commun. 2007, 364, 402- 409.
54. Parini, P., Gustafsson, U., Davis, M. A., Larsson, L. et al., Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1200- 1206.
55. Lei, L., Xiong, Y., Chen, J., Yang, J. B. et al., TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J. Lipid Res. 2009, 50, 1057- 1067.
56. Yang, J. B., Duan, Z. J., Yao, W., Lee, O. et al., Synergistic transcriptional activation of human Acyl-coenzyme A:cholesterol acyltransterase-1 gene by interferon-gamma and all-trans-retinoic acid THP-1 cells. J. Biol. Chem. 2001, 276, 20989- 20998.
57. Pramfalk, C., Davis, M. A., Eriksson, M., Rudel, L. L., Parini, P., Control of ACAT2 liver expression by HNF1. J. Lipid Res. 2005, 46, 1868- 1876.
58. Song, B. L., Qi, W., Wang, C. H., Yang, J. B. et al., Preparation of an anti-Cdx-2 antibody for analysis of different species Cdx-2 binding to acat2 promoter. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003, 35, 6- 12.
59. Song, B. L., Wang, C. H., Yao, X. M., Yang, L. et al., Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma. Biochem. J. 2006, 394, 617- 626.
60. Pramfalk, C., Karlsson, E., Groop, L., Rudel, L. L. et al., Control of ACAT2 liver expression by HNF4{alpha}: Lesson from MODY1 patients. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1235- 1241.
61. Yin, L., Ma, H., Ge, X., Edwards, P. A., Zhang, Y., Hepatic hepatocyte nuclear factor 4{alpha} is essential for maintaining triglyceride and cholesterol homeostasis. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 328- 336.
62. Langsted, A., Freiberg, J. J., Tybjaerg-Hansen, A., Schnohr, P., et al., Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: The Copenhagen City Heart Study with 31 years of follow-up. J. Intern. Med. 2010, 270, 65- 75.
63. Nordestgaard, B. G., Langsted, A., Freiberg, J. J., Nonfasting hyperlipidemia and cardiovascular disease. Curr. Drug Targets 2009, 10, 328- 335.
64. Rudel, L. L., Haines, J., Sawyer, J. K., Shah, R. et al., Hepatic origin of cholesteryl oleate in coronary artery atherosclerosis in African green monkeys. Enrichment by dietary monounsaturated fat. J. Clin. Invest. 1997, 100, 74- 83.
65. Parks, J. S., Bullock, B. C., Rudel, L. L., The reactivity of plasma phospholipids with lecithin:cholesterol acyltransferase is decreased in fish oil-fed monkeys. J. Biol. Chem. 1989, 264, 2545- 2551.
66. Kirkeby, K., Ingvaldsen, P., Bjerkedal, I., Fatty acid composition of serum lipids in men with myocardial infarction. Acta Med. Scand. 1972, 192, 513- 519.
67. Kingsbury, K. J., Morgan, D. M., Stovold, R., Brett, C. G., Anderson, J., Polyunsaturated fatty acids and myocardial infarction. Follow-up of patients with aortoiliac and femoropopliteal atherosclerosis. Lancet 1969, 2, 1325- 1329.
68. Lawrie, T. D., McAlpine, S. G., Rifkind, B. M., Robinson, J. F., Serum fatty-acid patterns in coronary-artery disease. Lancet 1961, 1, 421- 424.
69. Warensjo, E., Sundstrom, J., Vessby, B., Cederholm, T., Riserus, U., Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: A population-based prospective study. Am. J. Clin. Nutr. 2008, 88, 203- 209.
70. Ma, J., Folsom, A. R., Lewis, L., Eckfeldt, J. H., Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima-media thickness: The Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Clin. Nutr. 1997, 65, 551- 559.
71. Araya, J., Rodrigo, R., Videla, L. A., Thielemann, L. et al., Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. (Lond.) 2004, 106, 635- 643.
72. Zhu, L., Baker, S. S., Liu, W., Tao, M. H. et al., Lipid in the livers of adolescents with nonalcoholic steatohepatitis: Combined effects of pathways on steatosis. Metabolism 2011, 60, 1001- 1011.
73. Parini, P., Jiang, Z. Y., Einarsson, C., Eggertsen, G. et al., ACAT2 and human hepatic cholesterol metabolism: Identification of important gender-related differences in normolipidemic, non-obese Chinese patients. Atherosclerosis 2009, 207, 266- 271.
74. Yamagata, K., Oda, N., Kaisaki, P. J., Menzel, S. et al., Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996, 384, 455- 458.
75. Tomoda, X. X., Omura, H. S., Potential therapeutics for obesity and atherosclerosis: Inhibitors of neutral lipid metabolism from microorganisms. Pharmacol. Ther. 2007, 115, 375- 389.
76. Das, A., Davis, M. A., Tomoda, H., Omura, S., Rudel, L. L., Identification of the interaction site within acyl-CoA:cholesterol acyltransferase 2 for the isoform-specific inhibitor pyripyropene A. J. Biol. Chem. 2008, 283, 10453- 10460.
77. Lada, A. T., Davis, M., Kent, C., Chapman, J. et al., Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: Individual ACAT uniqueness. J. Lipid Res. 2004, 45, 378- 386.
78. Ohshiro, T., Matsuda, D., Sakai, K., Degirolamo, C. et al., Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1108- 1115.
79. Meuwese, M. C., de Groot, E., Duivenvoorden, R., Trip, M. D. et al., ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: The CAPTIVATE randomized trial. JAMA 2009, 301, 1131- 1139.
80. Parini, P., Eriksson, M., Rudel, L. L., Carotid atherosclerosis progression and ACAT inhibition. JAMA 2009, 302, 255. author reply 256-257.
81. Nissen, S. E., Tuzcu, E. M., Brewer, H. B., Sipahi, I. et al., Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 2006, 354, 1253- 1263.
82. Kitayama, K., Koga, T., Maeda, N., Inaba, T., Fujioka, T., Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits. Eur. J. Pharmacol. 2006, 539, 81- 88.
83. Kitayama, K., Tanimoto, T., Koga, T., Terasaka, N. et al., Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe. Eur. J. Pharmacol. 2006, 540, 121- 130.
84. Kotsuma, M., Hanzawa, H., Iwata, Y., Takahashi, K., Tokui, T., Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab. Dispos. 2008, 36, 1938- 1943.
85. Tardif, J. C., Gregoire, J., L'Allier, P. L., Anderson, T. J. et al., Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004, 110, 3372- 3377.
86. Sahi, J., Milad, M. A., Zheng, X., Rose, K. A. et al., Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther. 2003, 306, 1027- 1034.